By: IPP Bureau
Last updated : January 16, 2026 7:20 am
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has unveiled PatroLab, a next-generation digital twin platform designed to revolutionize bioprocess development and biologics manufacturing.
By integrating real-time process monitoring, Raman-based Process Analytical Technology (PAT), predictive in-silico modeling, and advanced machine learning, PatroLab delivers smarter analytics, proactive control, and accelerated decision-making. The platform promises to enhance process performance, minimize risks, shorten development timelines, and ensure consistent, high-quality biologics production.
Dr Chris Chen, CEO of WuXi Biologics, said: "As a leading global digital CRDMO partner, WuXi Biologics aims to turn the complex journey of biologics R&D and manufacturing into a predictable, accelerated success by building an industry-leading digital ecosystem rooted in our biologics expertise.
"The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing. By integrating real-time analytics, machine learning, predictive modeling and automated control into a unified platform, we enable partners to accelerate innovation while achieving unprecedented quality and efficiency. This is more than a technological breakthrough – it's a testament to our steadfast commitment to expediting the delivery of clients' life-saving therapies to patients worldwide."
At the heart of PatroLab is WuXi Biologics’ Raman PAT system, a leap from traditional offline testing to real-time, non-invasive monitoring of more than 40 critical process and product attributes. By increasing data density per batch nearly 1,000-fold, PatroLab empowers clients to apply Quality by Design (QbD) principles more effectively, accelerating development while maintaining operational excellence.
The system also rapidly characterizes complex raw materials, detecting subtle molecular variations in cell culture media and buffers to reduce batch variability and ensure consistent product quality.
PatroLab leverages a combination of data-driven and mechanistic modeling to create virtual bioprocess replicas, enabling predictive decision-making and “what-if” scenario testing. The platform identifies potential process risks, supports root cause analysis during scale-up, and detects metabolic or cellular bottlenecks, paving the way for continuous process improvement and robust product consistency.
The platform reduces deviations and batch rejection through end-to-end monitoring and alignment with critical quality attributes. Its predictive control and automated interventions minimize scale-up risks and operational variability, helping clients achieve faster, smarter, and more reliable manufacturing. PatroLab also supports real-time release testing (RTRT), aligning with FDA and EMA guidance to optimize manufacturing cycles.